Angiogenesis and antiangiogenic strategies in pancreatic cancer.
Despite numerous advances in the treatment of solid tumors, the prognosis of patients diagnosed with pancreatic cancer remains dismal. Results of both surgical and non-surgical treatment for pancreatic cancer have been extremely disappointing because of the tumors propensity to metastasize, failure of chemotherapy to achieve adequate levels within the tumor, and resistance of pancreatic cancer to cytotoxic agents. Current chemotherapeutic agents and radiation treatments rely on the rapidly dividing nature of tumor cells and are limited by their cytotoxic effects on normal cells. The need to exploit the difference between normal and malignant cells has resulted in an enormous amount of research into the process of tumor neovascularization. New agents are currently being developed that block tumor growth and metastasis through inhibition of angiogenesis. This article reviews the process of angiogenesis and antiangiogenic strategies with a special emphasis on pancreatic cancer.
Fisher
William E
WE
Houston VAMC, Baylor College of Medicine, Michael E. DeBakey Department of Surgery, Houston, TX 77030, USA.
Berger
David H
DH
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D006801:Humans; D009389:Neovascularization, Pathologic; D010190:Pancreatic Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000209:etiology
D020533:Angiogenesis Inhibitors